JP2016509009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509009A5 JP2016509009A5 JP2015557068A JP2015557068A JP2016509009A5 JP 2016509009 A5 JP2016509009 A5 JP 2016509009A5 JP 2015557068 A JP2015557068 A JP 2015557068A JP 2015557068 A JP2015557068 A JP 2015557068A JP 2016509009 A5 JP2016509009 A5 JP 2016509009A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- antigen
- binding fragment
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 30
- 239000012634 fragment Substances 0.000 claims 27
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 238000000034 method Methods 0.000 claims 16
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 14
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 14
- 206010020751 Hypersensitivity Diseases 0.000 claims 8
- 208000026935 allergic disease Diseases 0.000 claims 8
- 230000007815 allergy Effects 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 230000002062 proliferating effect Effects 0.000 claims 6
- 208000035473 Communicable disease Diseases 0.000 claims 5
- -1 Fas Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 108010057466 NF-kappa B Proteins 0.000 claims 4
- 102000003945 NF-kappa B Human genes 0.000 claims 4
- 239000012190 activator Substances 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 210000004698 lymphocyte Anatomy 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 210000003289 regulatory T cell Anatomy 0.000 claims 4
- DAPAQENNNINUPW-IDAMAFBJSA-N rocaglamide Chemical compound C1=CC(OC)=CC=C1[C@]1([C@@H]([C@H]([C@H]2O)C(=O)N(C)C)C=3C=CC=CC=3)[C@]2(O)C2=C(OC)C=C(OC)C=C2O1 DAPAQENNNINUPW-IDAMAFBJSA-N 0.000 claims 4
- 150000003384 small molecules Chemical class 0.000 claims 4
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000005260 human cell Anatomy 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 claims 3
- DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical compound CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims 2
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 2
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 108090000174 Interleukin-10 Proteins 0.000 claims 2
- 102000003814 Interleukin-10 Human genes 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims 2
- 102100033467 L-selectin Human genes 0.000 claims 2
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims 2
- DAPAQENNNINUPW-UHFFFAOYSA-N endo rocaglamide Natural products C1=CC(OC)=CC=C1C1(C(C(C2O)C(=O)N(C)C)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 DAPAQENNNINUPW-UHFFFAOYSA-N 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 102000042567 non-coding RNA Human genes 0.000 claims 2
- 108091027963 non-coding RNA Proteins 0.000 claims 2
- SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 claims 2
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 claims 1
- ILVFNAZMSMNXJG-RMKNXTFCSA-N 1-fluoro-2-[(e)-2-(4-methoxyphenyl)ethenyl]benzene Chemical compound C1=CC(OC)=CC=C1\C=C\C1=CC=CC=C1F ILVFNAZMSMNXJG-RMKNXTFCSA-N 0.000 claims 1
- AYKMXKNVEUMLFQ-UHFFFAOYSA-N 2-(1,8-naphthyridin-2-yl)phenol Chemical group OC1=CC=CC=C1C1=CC=C(C=CC=N2)C2=N1 AYKMXKNVEUMLFQ-UHFFFAOYSA-N 0.000 claims 1
- BOIPLTNGIAPDBY-UHFFFAOYSA-N 2-[6-(4-chlorophenoxy)hexyl]-1-cyano-3-pyridin-4-ylguanidine Chemical compound C1=CC(Cl)=CC=C1OCCCCCCN=C(NC#N)NC1=CC=NC=C1 BOIPLTNGIAPDBY-UHFFFAOYSA-N 0.000 claims 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 claims 1
- XCHLNGBTHLJLFG-UHFFFAOYSA-N 3-chloro-4-nitro-n-(5-nitro-1,3-thiazol-2-yl)benzamide Chemical compound S1C([N+](=O)[O-])=CN=C1NC(=O)C1=CC=C([N+]([O-])=O)C(Cl)=C1 XCHLNGBTHLJLFG-UHFFFAOYSA-N 0.000 claims 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 claims 1
- AEOGPIJVSQTAII-UHFFFAOYSA-N 4-(furan-2-ylmethyl)-1,4-thiazinane 1,1-dioxide Chemical compound C1CS(=O)(=O)CCN1CC1=CC=CO1 AEOGPIJVSQTAII-UHFFFAOYSA-N 0.000 claims 1
- JFSXSNSCPNFCDM-UHFFFAOYSA-N 6-(benzenesulfinyl)tetrazolo[1,5-b]pyridazine Chemical compound C1=CC2=NN=NN2N=C1S(=O)C1=CC=CC=C1 JFSXSNSCPNFCDM-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- OSSDUQKWVVZIGP-UHFFFAOYSA-N Aromaticin Natural products CC1CC2OC(=O)C(=C)C2CC2(C)C(=O)C=CC12 OSSDUQKWVVZIGP-UHFFFAOYSA-N 0.000 claims 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- VHKZGNPOHPFPER-ONNFQVAWSA-N BAY11-7085 Chemical compound CC(C)(C)C1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 VHKZGNPOHPFPER-ONNFQVAWSA-N 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- NYSZJNUIVUBQMM-BQYQJAHWSA-N Cardamonin Chemical compound COC1=CC(O)=CC(O)=C1C(=O)\C=C\C1=CC=CC=C1 NYSZJNUIVUBQMM-BQYQJAHWSA-N 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011038 Cold agglutinin disease Diseases 0.000 claims 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- IEPRKVQEAMIZSS-UHFFFAOYSA-N Di-Et ester-Fumaric acid Natural products CCOC(=O)C=CC(=O)OCC IEPRKVQEAMIZSS-UHFFFAOYSA-N 0.000 claims 1
- IEPRKVQEAMIZSS-WAYWQWQTSA-N Diethyl maleate Chemical compound CCOC(=O)\C=C/C(=O)OCC IEPRKVQEAMIZSS-WAYWQWQTSA-N 0.000 claims 1
- 206010013700 Drug hypersensitivity Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- ZVLOPMNVFLSSAA-UHFFFAOYSA-N Heleanalin Natural products CC1CC2OC(=O)C(=C)C2C(O)C2(C)C(=O)C=CC12 ZVLOPMNVFLSSAA-UHFFFAOYSA-N 0.000 claims 1
- RFBYGVGDYMSKTD-UHFFFAOYSA-N Helenalin Natural products CC1CC2OC(=O)C(=C)C2C(O)C3C(C)C(=O)C=C13 RFBYGVGDYMSKTD-UHFFFAOYSA-N 0.000 claims 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- YMFNPBSZFWXMAD-UHFFFAOYSA-N JSH-23 Chemical compound NC1=CC(C)=CC=C1NCCCC1=CC=CC=C1 YMFNPBSZFWXMAD-UHFFFAOYSA-N 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- AFTUDGRDUWDYHE-UHFFFAOYSA-N Mexicanin I Natural products CC1CC2OC(=O)C(=C)C2C(O)C3(C)C1CC=C3C AFTUDGRDUWDYHE-UHFFFAOYSA-N 0.000 claims 1
- 108010047660 Mitochondrial intermediate peptidase Proteins 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 239000005480 Olmesartan Substances 0.000 claims 1
- BIVQBWSIGJFXLF-UHFFFAOYSA-N PPM-18 Chemical compound C=1C(=O)C2=CC=CC=C2C(=O)C=1NC(=O)C1=CC=CC=C1 BIVQBWSIGJFXLF-UHFFFAOYSA-N 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010048908 Seasonal allergy Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 101710183280 Topoisomerase Proteins 0.000 claims 1
- 241000159243 Toxicodendron radicans Species 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- WKMYTPCPAWZWII-UHFFFAOYSA-N [2-(4-acetyloxyphenyl)-2-chloroethyl]-methylazanium;chloride Chemical compound Cl.CNCC(Cl)C1=CC=C(OC(C)=O)C=C1 WKMYTPCPAWZWII-UHFFFAOYSA-N 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- NYSZJNUIVUBQMM-UHFFFAOYSA-N alpinetin chalcone Natural products COC1=CC(O)=CC(O)=C1C(=O)C=CC1=CC=CC=C1 NYSZJNUIVUBQMM-UHFFFAOYSA-N 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 claims 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims 1
- 229940022405 astaxanthin Drugs 0.000 claims 1
- 235000013793 astaxanthin Nutrition 0.000 claims 1
- 239000001168 astaxanthin Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 claims 1
- GORBWKHYCDIEIF-UHFFFAOYSA-N azanium;pyrrolidine;carbamodithioate Chemical compound [NH4+].NC([S-])=S.C1CCNC1 GORBWKHYCDIEIF-UHFFFAOYSA-N 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical group C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000002143 bronchus adenoma Diseases 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960002563 disulfiram Drugs 0.000 claims 1
- 239000012990 dithiocarbamate Substances 0.000 claims 1
- 150000004659 dithiocarbamates Chemical class 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 201000005311 drug allergy Diseases 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- WDKYDMULARNCIS-UHFFFAOYSA-N ethyl caffeoate Natural products CCOC(=O)C=CC1=CC=C(O)C(O)=C1 WDKYDMULARNCIS-UHFFFAOYSA-N 0.000 claims 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 claims 1
- 229940103893 gliotoxin Drugs 0.000 claims 1
- 229930190252 gliotoxin Natural products 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- ZVLOPMNVFLSSAA-XEPQRQSNSA-N helenalin Chemical compound C[C@@H]1C[C@H]2OC(=O)C(=C)[C@H]2[C@H](O)[C@]2(C)C(=O)C=C[C@@H]12 ZVLOPMNVFLSSAA-XEPQRQSNSA-N 0.000 claims 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 claims 1
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 claims 1
- 201000006866 hypopharynx cancer Diseases 0.000 claims 1
- 230000002267 hypothalamic effect Effects 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 230000002989 hypothyroidism Effects 0.000 claims 1
- 208000033065 inborn errors of immunity Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 1
- 229960004963 mesalazine Drugs 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 1
- 229960005117 olmesartan Drugs 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 201000002511 pituitary cancer Diseases 0.000 claims 1
- 208000010626 plasma cell neoplasm Diseases 0.000 claims 1
- 210000004224 pleura Anatomy 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 229960004025 sodium salicylate Drugs 0.000 claims 1
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 claims 1
- 208000037969 squamous neck cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000037965 uterine sarcoma Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 210000000239 visual pathway Anatomy 0.000 claims 1
- 230000004400 visual pathway Effects 0.000 claims 1
- 229930182877 withaferin Natural products 0.000 claims 1
- YCGBUPXEBUFYFV-UHFFFAOYSA-N withaferin A Natural products CC(C1CC(=C(CO)C(=O)O1)C)C2CCC3C4CC5OC56C(O)C=CC(O)C6(C)C4CCC23C YCGBUPXEBUFYFV-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361762136P | 2013-02-07 | 2013-02-07 | |
| US61/762,136 | 2013-02-07 | ||
| US201361763217P | 2013-02-11 | 2013-02-11 | |
| US61/763,217 | 2013-02-11 | ||
| PCT/US2014/015101 WO2014124134A1 (en) | 2013-02-07 | 2014-02-06 | Methods for expansion or depletion of t-regulatory cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018127922A Division JP6808688B2 (ja) | 2013-02-07 | 2018-07-05 | Ｔ制御性細胞の増殖または枯渇方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016509009A JP2016509009A (ja) | 2016-03-24 |
| JP2016509009A5 true JP2016509009A5 (OSRAM) | 2017-03-09 |
| JP6367836B2 JP6367836B2 (ja) | 2018-08-01 |
Family
ID=51300130
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015557068A Active JP6367836B2 (ja) | 2013-02-07 | 2014-02-06 | Ｔ制御性細胞の増殖または枯渇方法 |
| JP2018127922A Active JP6808688B2 (ja) | 2013-02-07 | 2018-07-05 | Ｔ制御性細胞の増殖または枯渇方法 |
| JP2020204143A Active JP7257374B2 (ja) | 2013-02-07 | 2020-12-09 | Ｔ制御性細胞の増殖または枯渇方法 |
| JP2022207092A Pending JP2023040077A (ja) | 2013-02-07 | 2022-12-23 | Ｔ制御性細胞の増殖または枯渇方法 |
| JP2025131209A Pending JP2025166059A (ja) | 2013-02-07 | 2025-08-06 | Ｔ制御性細胞の増殖または枯渇方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018127922A Active JP6808688B2 (ja) | 2013-02-07 | 2018-07-05 | Ｔ制御性細胞の増殖または枯渇方法 |
| JP2020204143A Active JP7257374B2 (ja) | 2013-02-07 | 2020-12-09 | Ｔ制御性細胞の増殖または枯渇方法 |
| JP2022207092A Pending JP2023040077A (ja) | 2013-02-07 | 2022-12-23 | Ｔ制御性細胞の増殖または枯渇方法 |
| JP2025131209A Pending JP2025166059A (ja) | 2013-02-07 | 2025-08-06 | Ｔ制御性細胞の増殖または枯渇方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US9821010B2 (OSRAM) |
| EP (2) | EP3936137A1 (OSRAM) |
| JP (5) | JP6367836B2 (OSRAM) |
| DK (1) | DK2953634T3 (OSRAM) |
| ES (1) | ES2885423T3 (OSRAM) |
| HR (1) | HRP20211353T1 (OSRAM) |
| PL (1) | PL2953634T3 (OSRAM) |
| PT (1) | PT2953634T (OSRAM) |
| WO (1) | WO2014124134A1 (OSRAM) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6031552A (en) * | 1994-11-18 | 2000-02-29 | Heidelberger Druckmaschinen Ag | Printing device with patterned recording surface |
| ES2885423T3 (es) | 2013-02-07 | 2021-12-13 | Massachusetts Gen Hospital | Procedimientos para la expansión o el empobrecimiento de células T reguladoras |
| JP6560200B2 (ja) | 2013-10-17 | 2019-08-14 | ザ ジェネラル ホスピタル コーポレイション | 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 |
| EP3265493B1 (en) * | 2015-03-02 | 2024-01-10 | 180 Therapeutics LP | Method of treating a localized fibrotic disorder using an il-33 antagonist |
| EP3283619B1 (en) | 2015-04-17 | 2023-04-05 | Novartis AG | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| WO2016187068A1 (en) * | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| AU2016297014B2 (en) | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| EP3340999A4 (en) * | 2015-08-28 | 2019-06-12 | The General Hospital Corporation | AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES |
| US11266730B2 (en) | 2015-09-29 | 2022-03-08 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for BCG therapy |
| IL258935B2 (en) * | 2015-10-28 | 2024-08-01 | Life Tech As | Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio |
| CA3004830A1 (en) * | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| AU2016362129A1 (en) | 2015-12-04 | 2018-06-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| US9989543B2 (en) | 2016-01-11 | 2018-06-05 | Autotelic, Llc | Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension |
| CN116715767A (zh) * | 2016-05-13 | 2023-09-08 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
| EP3475301B1 (en) | 2016-06-22 | 2023-01-04 | Université Paris-Est Créteil Val de Marne | Prevention or treatment of hematologic malignancy relapse using a tnfr2 antagonist |
| JP7054209B2 (ja) * | 2016-11-21 | 2022-04-13 | 国立研究開発法人医薬基盤・健康・栄養研究所 | エピトープ均質化抗体パネル、ならびにその作製方法および利用 |
| AU2018234827B2 (en) | 2017-03-15 | 2024-04-04 | Orca Biosystems Inc. | Compositions and methods for hematopoietic stem cell transplants |
| SG11201907434RA (en) | 2017-03-22 | 2019-10-30 | Novartis Ag | Compositions and methods for immunooncology |
| US11389480B2 (en) | 2017-05-19 | 2022-07-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody targeting TNFR2 for cancer immunotherapy |
| US11618884B2 (en) * | 2017-11-14 | 2023-04-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Regulatory T cells genetically modified for the lymphotoxin alpha gene and uses thereof |
| AU2018375151B2 (en) * | 2017-11-29 | 2025-06-26 | Spinalcyte Llc | Interaction of fibroblasts and immune cells for activation and uses thereof |
| WO2020061210A1 (en) * | 2018-09-18 | 2020-03-26 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
| MX2021005151A (es) * | 2018-11-01 | 2021-07-15 | Bioinvent Int Ab | Novedosas moleculas de anticuerpos anti-tnfr2 agonistas. |
| CA3117864A1 (en) | 2018-11-01 | 2020-05-07 | Bioinvent International Ab | Novel antagonistic anti tnfr2 antibody molecules |
| CN109609616B (zh) * | 2018-11-05 | 2021-12-07 | 复旦大学附属华山医院 | Hla-a*02:01和hla-c*01:02在丹参酮所致药疹中的用途 |
| EP3880711A4 (en) * | 2018-11-15 | 2022-12-28 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
| EP3930846A1 (en) * | 2019-03-01 | 2022-01-05 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
| CN109846863B (zh) * | 2019-03-12 | 2021-09-21 | 成都金瑞基业生物科技有限公司 | 和厚朴酚的用途 |
| CN110179790A (zh) * | 2019-07-02 | 2019-08-30 | 广西医科大学 | 一种抑制肝星状细胞活化药物的制备及应用 |
| CA3154643A1 (en) * | 2019-09-17 | 2021-03-25 | Apexigen, Inc. | Anti-tnfr2 antibodies and methods of use |
| CN110693907A (zh) * | 2019-11-07 | 2020-01-17 | 南通大学 | 调节性T细胞在制备治疗或预防Zika病毒感染所致不良妊娠药物方面的应用 |
| CN110974818A (zh) * | 2019-12-31 | 2020-04-10 | 中国药科大学 | 咖啡酸苯乙酯在制备肝再生药物中的应用 |
| CA3166898A1 (en) * | 2020-01-06 | 2021-07-15 | Hifibio (Hk) Limited | Anti-tnfr2 antibody and uses thereof |
| JP7101433B2 (ja) * | 2020-03-30 | 2022-07-15 | 国立研究開発法人医薬基盤・健康・栄養研究所 | エピトープ領域架橋型バイパラトピック抗体、及びそれを製造する方法 |
| TWI878554B (zh) * | 2020-06-12 | 2025-04-01 | 大陸商南京維立志博生物科技股份有限公司 | 結合ｔｎｆｒ２的抗體及其用途 |
| CN113825832B (zh) * | 2020-07-28 | 2024-12-13 | 浙江大学 | 一种体外诱导CD4+Foxp3+CD69+Treg的扩增方法及其用途 |
| KR20230078657A (ko) | 2020-08-27 | 2023-06-02 | 에노시 테라퓨틱스 코퍼레이션 | 자가면역 질환 및 암을 치료하기 위한 방법 및 조성물 |
| CN111920802B (zh) * | 2020-09-11 | 2024-01-23 | 华侨大学 | 穿心莲内酯在制备防治成人t细胞白血病药物的应用 |
| CN115925929A (zh) | 2021-09-22 | 2023-04-07 | 上海康岱生物医药技术股份有限公司 | 抗tnfr2单克隆抗体及其应用 |
| WO2025049818A1 (en) | 2023-08-29 | 2025-03-06 | Enosi Therapeutics Corporation | Tnfr1 antagonists lacking agonist activity and uses thereof |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4309418A (en) | 1980-03-25 | 1982-01-05 | Sloan-Kettering Research Institute For Cancer | Anti-tumor agent from human serum and process |
| SE8204382L (sv) | 1981-07-21 | 1983-01-22 | Hayashibara Biochem Lab | Sett att framstella malcellysfaktor och anvendning derav |
| US4457916A (en) | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3582183D1 (de) | 1984-03-06 | 1991-04-25 | Dainippon Pharmaceutical Co | Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid. |
| US5288852A (en) | 1984-03-06 | 1994-02-22 | Dainippon Pharmaceutical Co., Ltd. | Human tumor necrosis factor polypeptides |
| US4879226A (en) | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
| DE3423234A1 (de) | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
| GR851626B (OSRAM) | 1984-07-05 | 1985-11-26 | Genentech Inc | |
| EP0200748B1 (en) | 1984-10-15 | 1991-02-06 | Cetus Corporation | Human tumor necrosis factor |
| US4677064A (en) | 1984-11-09 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| ATE73856T1 (de) | 1984-12-21 | 1992-04-15 | Biogen Inc | Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren. |
| US4681760A (en) | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
| US5059530A (en) | 1985-09-30 | 1991-10-22 | Suntory Ltd. | Expression vector for human TNF |
| US6150090A (en) | 1986-01-09 | 2000-11-21 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| ATE107362T1 (de) | 1986-06-20 | 1994-07-15 | Dainippon Pharmaceutical Co | Polypeptid-mutanten des menschlichen tnf und für diese mutanten codierende dns. |
| US5002876A (en) | 1986-09-22 | 1991-03-26 | Phillips Petroleum Company | Yeast production of human tumor necrosis factor |
| US4985241A (en) | 1986-11-21 | 1991-01-15 | Cetus Corporation | Therapeutic combination of free-radical scavenger and tumor necrosis factor |
| US4963354A (en) | 1987-01-21 | 1990-10-16 | Genentech, Inc. | Use of tumor necrosis factor (TNF) as an adjuvant |
| WO1988006625A2 (en) | 1987-02-26 | 1988-09-07 | Cetus Corporation | Arginine-depleted human tumor necrosis factor |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5215743A (en) | 1988-04-13 | 1993-06-01 | Maninder Singh | Tumor necrosis factor formulations |
| JPH0797997B2 (ja) | 1988-04-28 | 1995-10-25 | 帝人株式会社 | 新規生理活性ポリペプチド |
| US5370870A (en) | 1989-10-06 | 1994-12-06 | Genentech, Inc. | Method for protection against reactive oxygen species |
| US5283058A (en) | 1990-08-30 | 1994-02-01 | The General Hospital Corporation | Methods for inhibiting rejection of transplanted tissue |
| US5593698A (en) | 1990-10-31 | 1997-01-14 | Autoimmune, Inc. | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides |
| CA2055168A1 (en) | 1990-11-21 | 1992-05-22 | Walter Fiers | Tnf-muteins |
| US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| DK0600930T3 (da) | 1991-08-02 | 2002-12-02 | Denise L Faustman | Diagnose og behandling af autoimmune sygdomme |
| US6984380B1 (en) | 1991-08-02 | 2006-01-10 | Denise L. Faustman | Treatment of diseases involving faulty MHC class I antigen complex presentation |
| US5139481A (en) | 1991-08-07 | 1992-08-18 | The General Hospital Corporation | Treatment for type II diabetes |
| US5843425A (en) | 1992-02-19 | 1998-12-01 | The General Hospital Corporation | Transplantation and graft-versus-host-disease |
| SK376492A3 (en) | 1992-04-02 | 1995-06-07 | Hoffmann La Roche | Tnf - muteins and method of their production |
| EP0639979B1 (en) | 1992-04-23 | 2001-10-04 | Sloan-Kettering Institute For Cancer Research | LIGAND FOR THE c-KIT RECEPTOR AND METHODS OF USE THEREOF |
| US5939532A (en) | 1993-09-07 | 1999-08-17 | Kyowa Hakko Kogyo Co., Ltd | Humanized antibodies to ganglioside GM2 |
| WO1994009137A1 (en) | 1992-10-15 | 1994-04-28 | Genentech, Inc. | Antibodies against type 2 tumor necrosis factor receptor |
| US5843452A (en) | 1992-11-09 | 1998-12-01 | Pharmagenesis, Inc. | Immunotherapy composition and method |
| US5560908A (en) | 1993-01-22 | 1996-10-01 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Therapeutic agent for NIDDM |
| AU7386094A (en) * | 1993-07-29 | 1995-02-28 | Bernhard Heising | T-lymphocyte-containing pharmaceutical composition for treating infections |
| US5728385A (en) | 1993-08-12 | 1998-03-17 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
| US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
| US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
| US5874301A (en) | 1994-11-21 | 1999-02-23 | National Jewish Center For Immunology And Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
| AU7010996A (en) | 1995-08-30 | 1997-03-19 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Selective elimination of t cells that recognize specific preselected targets |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| US5874306A (en) | 1996-12-12 | 1999-02-23 | The Regents Of The University Of California | Culturing human pancreatic endocrine cells in medium containing extracellular matrix from human bladder carcinoma cells |
| US6046031A (en) | 1997-01-21 | 2000-04-04 | Human Genome Sciences, Inc. | Metalloproteinases |
| US6177076B1 (en) | 1997-12-09 | 2001-01-23 | Thomas Jefferson University | Method of treating bladder cancer with wild type vaccinia virus |
| US6617171B2 (en) | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| US6284879B1 (en) | 1998-04-16 | 2001-09-04 | The General Hospital Corporation | Transport associated protein splice variants |
| US6165737A (en) | 1998-04-16 | 2000-12-26 | The University Of Texas System Board Of Regents | DNA fragmentation factor involved in apoptosis |
| CA2324995A1 (en) | 1998-04-17 | 1999-10-28 | University Of Vermont And State Agricultural College | Methods and products related to metabolic interactions in disease |
| CA2328509A1 (en) | 1998-05-18 | 1999-11-25 | Applied Research Systems Ars Holding N.V | Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions |
| US7485293B1 (en) | 1999-02-18 | 2009-02-03 | Faustman Denise L | Method for inhibiting transplant rejection |
| US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
| US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
| JP3589912B2 (ja) | 1999-09-03 | 2004-11-17 | 泰久 福井 | ホスファチジルイノシトール−３，４−二リン酸を認識するモノクローナル抗体 |
| WO2001039784A1 (en) | 1999-12-06 | 2001-06-07 | The General Hospital Corporation | Pancreatic stem cells and their use in transplantation |
| WO2001044472A1 (en) | 1999-12-16 | 2001-06-21 | Amgen, Inc. | Tnfr/opg-like molecules and uses thereof |
| US6414218B1 (en) | 2000-01-18 | 2002-07-02 | The General Hospital Corporation | Mouse model for rheumatoid arthritis |
| US20030215450A1 (en) | 2000-05-26 | 2003-11-20 | Blake Simon M | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| AU2001294834A1 (en) | 2000-09-26 | 2002-04-08 | Beth Israel Deaconess Medical Center | Recombinant bcg vaccines for the prevention and treatment of cancer |
| US20040031066A9 (en) | 2001-01-18 | 2004-02-12 | Faustman Denise L. | Mouse model for rheumatoid arthritis |
| US7582313B2 (en) | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
| US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| AU2003290948A1 (en) | 2002-11-15 | 2004-06-15 | The General Hospital Corporation | Screening methods to identify treatments for autoimmune disease |
| US7510877B2 (en) | 2003-09-26 | 2009-03-31 | The Regents Of The University Of Michigan | Hematopoietic stem cell identification and isolation |
| CA2548787A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition specifically binding to ganglioside gm2 |
| US8563308B2 (en) | 2004-03-10 | 2013-10-22 | The Rockefeller University | Culture-expanded T suppressor cells and methods of use thereof |
| EP1765988B1 (en) * | 2004-05-27 | 2017-09-20 | The Trustees of The University of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| CN101084014A (zh) | 2004-10-08 | 2007-12-05 | 杜门蒂斯有限公司 | 抗肿瘤坏死因子受体1的单域抗体及其使用方法 |
| US20080102054A1 (en) | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
| EP1875247B1 (en) | 2005-04-11 | 2011-02-02 | Cambridge Enterprise Limited | Selective modulation of tumour necrosis factor receptors in therapy |
| EP2107115A1 (en) | 2007-01-24 | 2009-10-07 | Kyowa Hakko Kirin Co., Ltd. | Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2 |
| JP2010531138A (ja) * | 2007-06-13 | 2010-09-24 | ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー | 制御性ｔ細胞ならびに同製造および使用方法 |
| US8900816B2 (en) | 2007-07-19 | 2014-12-02 | Duke University | Assay for anti-EGFRvIII antibodies |
| US8314213B2 (en) * | 2008-04-18 | 2012-11-20 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
| CA2758542A1 (en) * | 2009-04-17 | 2010-10-21 | New York University | Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof |
| WO2010124259A1 (en) | 2009-04-24 | 2010-10-28 | Centre Hospitalier Universitaire Sainte-Justine | Allosteramers for tnf receptors and uses thereof |
| CA2760305A1 (en) * | 2009-04-28 | 2010-11-04 | Boehringer Ingelheim International Gmbh | Ex-vivo treatment of immunological disorders with pkc-theta inhibitors |
| US8530392B2 (en) | 2009-05-13 | 2013-09-10 | Shionogi & Co., Ltd. | Test agent for visceral obesity and use thereof |
| WO2011107989A1 (en) | 2010-03-01 | 2011-09-09 | Lostam Biopharmaceuticals Ltd | Improved therapeutic antibodies against flagellated pseudomonas aeruginosa |
| JP6066732B2 (ja) | 2010-03-05 | 2017-01-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 標的免疫調節抗体および融合タンパク質に基づく組成物および方法 |
| US20130064831A1 (en) | 2010-05-17 | 2013-03-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| CA2810465C (en) | 2010-09-16 | 2018-10-02 | Baliopharm Ag | Anti-hutnfr1 antibody |
| US20140121123A1 (en) | 2010-10-29 | 2014-05-01 | Kevin Caili Wang | Methods for diversifying antibodies, antibodies derived therefrom and uses thereof |
| EP2468764A1 (en) | 2010-12-24 | 2012-06-27 | Rijksuniversiteit te Groningen | TNF family ligand variants |
| WO2012122464A1 (en) | 2011-03-10 | 2012-09-13 | New York University | Methods and compositions for modulating tnf/tnfr signaling |
| GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| WO2013165982A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-human cytomegalvirus antibodies and use thereof |
| JP5922845B2 (ja) | 2012-07-18 | 2016-05-24 | 京セラ株式会社 | セルラ通信システムにおける装置間通信の干渉管理 |
| ES2885423T3 (es) | 2013-02-07 | 2021-12-13 | Massachusetts Gen Hospital | Procedimientos para la expansión o el empobrecimiento de células T reguladoras |
| EP3590967A1 (en) | 2014-03-24 | 2020-01-08 | Cancer Research Technology Limited | Modified antibodies containing modified igg2 domains which elicit agonist properties and use thereof |
| CN114099671A (zh) | 2014-08-12 | 2022-03-01 | 鳄鱼生物科学公司 | 利用抗cd40抗体的组合疗法 |
| US9172855B1 (en) | 2014-08-28 | 2015-10-27 | Avigilon Corporation | Pendant housing for a camera |
| WO2016187068A1 (en) | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| EP3340999A4 (en) | 2015-08-28 | 2019-06-12 | The General Hospital Corporation | AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES |
| CA3004830A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| CN116715767A (zh) | 2016-05-13 | 2023-09-08 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
| CA3033665A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
| CA3038909A1 (en) | 2016-09-29 | 2018-04-05 | Amgen Inc. | Low-viscosity antigen binding proteins and methods of making them |
| JP7054209B2 (ja) | 2016-11-21 | 2022-04-13 | 国立研究開発法人医薬基盤・健康・栄養研究所 | エピトープ均質化抗体パネル、ならびにその作製方法および利用 |
| EA201991207A1 (ru) | 2016-12-19 | 2019-12-30 | Гленмарк Фармасьютикалс С.А. | Новые агонисты tnfr и их применение |
| EP3707163A4 (en) | 2017-11-09 | 2021-08-18 | The General Hospital Corporation | POLYPEPTIDES ANTAGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY |
| KR20210061350A (ko) * | 2018-08-20 | 2021-05-27 | 더 제너럴 하스피탈 코포레이션 | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 폴리펩티드 |
-
2014
- 2014-02-06 ES ES14748807T patent/ES2885423T3/es active Active
- 2014-02-06 HR HRP20211353TT patent/HRP20211353T1/hr unknown
- 2014-02-06 US US14/764,325 patent/US9821010B2/en active Active
- 2014-02-06 WO PCT/US2014/015101 patent/WO2014124134A1/en not_active Ceased
- 2014-02-06 JP JP2015557068A patent/JP6367836B2/ja active Active
- 2014-02-06 DK DK14748807.6T patent/DK2953634T3/da active
- 2014-02-06 EP EP21175520.2A patent/EP3936137A1/en active Pending
- 2014-02-06 EP EP14748807.6A patent/EP2953634B1/en active Active
- 2014-02-06 PL PL14748807T patent/PL2953634T3/pl unknown
- 2014-02-06 PT PT147488076T patent/PT2953634T/pt unknown
-
2017
- 2017-11-20 US US15/817,713 patent/US10765700B2/en active Active
-
2018
- 2018-07-05 JP JP2018127922A patent/JP6808688B2/ja active Active
-
2020
- 2020-08-06 US US16/986,755 patent/US11844814B2/en active Active
- 2020-12-09 JP JP2020204143A patent/JP7257374B2/ja active Active
-
2022
- 2022-12-23 JP JP2022207092A patent/JP2023040077A/ja active Pending
-
2023
- 2023-12-14 US US18/540,207 patent/US20240216431A1/en active Pending
-
2025
- 2025-08-06 JP JP2025131209A patent/JP2025166059A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016509009A5 (OSRAM) | ||
| MX2022003249A (es) | Anticuerpos anti receptor del factor de necrosis tumoral 2 (tnfr2) y métodos de uso. | |
| JP2018515474A5 (OSRAM) | ||
| EP4317185A3 (en) | Fully-human post-translationally modified antibody therapeutics | |
| JP2020515247A5 (OSRAM) | ||
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| MY205774A (en) | Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof | |
| JP2020536109A5 (OSRAM) | ||
| WO2020076969A3 (en) | Anti-lap antibody variants and uses thereof | |
| JP2018512170A5 (OSRAM) | ||
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| MX2020013062A (es) | Anticuerpos anti proteina relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticoides (gitr) y sus metodos de uso. | |
| MX2022007774A (es) | Anticuerpos de union a abril modificados. | |
| CR20160319A (es) | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este | |
| MX2009011996A (es) | Anticuerpos anti-coestimulador inducible y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunologica. | |
| EP3991748A3 (en) | Anti-sortilin antibodies and methods of use thereof | |
| PH12019502007A1 (en) | Anti-gitr antibodies and methods of use thereof | |
| MX394165B (es) | Anticuerpos anti-receptor ccr7 humanizados. | |
| PH12020552235A1 (en) | Anti-cd40 antibodies for use in treating autoimmune disease | |
| PH12016500237A1 (en) | Novel anti-human tslp receptor antibody | |
| JP2017525343A5 (OSRAM) | ||
| JP2017508475A5 (OSRAM) | ||
| JP2016502515A5 (OSRAM) | ||
| MX2019014375A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. | |
| RU2013106217A (ru) | Гибридный белок из антитела против мнс и противовирусного цитокина |